Rx Naloxone Marketer's OTC Switch Proposal For Nasal Spray Gets Priority Review From FDA

 
• By Malcolm Spicer
  
With priority review granted for Emergent's sNDA for OTC Narcan nasal spay. FDA’s deadline under PDUFA for a decision is 29 March. • Source: Shutterstock

More from Rx-to-OTC Switch

More from Health